Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.
MarketWatch Techen
For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.
This is a short summary published by AI Global Wire. The full article is owned and hosted by MarketWatch Tech — open it there to read it in full.
Read the full story at MarketWatch Tech- Anthropic
- Forskning
Related AI news
- Anthropic's IPO prospectus: H1 2026 revenue of $16.3B, ~20% from two customers, vs. $1.1B in H1 2025, and an $80.7B net loss driven by accounting charges (Anissa Gardizy/Wall Street Journal)Techmeme · October 20, 2026
- FBI tutki ”vessapaperivakoojan” puhelimen: Yksi kansio paljasti hätkähdyttävän kytköksenTivi · October 20, 2026
- Deepseek open-sources the inference engine that powers its fastest and cheapest AI modelThe Decoder · October 20, 2026
- Meta pauses Muse sharing after researchers find AI chats on the webThe Verge AI · October 20, 2026
- Eric Schmidt reportedly owns about half as much of Anthropic as CEO Dario AmodeiTechCrunch AI · October 20, 2026
- Exclusive: OpenAI has acquired Orchestra BioAxios · October 20, 2026